Okomera has developed a proprietary technology platform that transforms patient biopsies into multiple miniaturized tumor avatars, enabling rapid assessment of treatment response in real-world conditions. Designed as a decentralized lab for clinicians and biopharma companies, the platform seamlessly converges cutting-edge hardware, software, and biological technologies into a single integrated system, making functional precision medicine accessible at scale. We are building a future where every cancer patient receives the right treatment from the start.
| Website | http://www.okomera.com |
| Employees | 24 (21 on RocketReach) |
| Founded | 2020 |
| Industry | Biotechnology Research |
| Keywords | Drug Discovery, Drug Development, Target Validation, Preclinical Testing, Pharmaceutical Research, Therapeutic Development, Assay Development, Cell Based Assays, Biotechnology, High Throughput Screening, Immunology, In Vitro Assays, Microfluidics, Biosensors, Molecular Diagnostics, Precision Medicine |
| Competitors | Statkraft, Enel Green Power, NextEra Energy, Inc., Vattenfall, EDP Renewables, Iberdrola Renewables, Gamesa, First Solar, Brookfield Asset Management, Duke Energy Corporation +41 more (view full list) |
Looking for a particular Okomera employee's phone or email?
Raphaël Tomasi is the Co-founder and VP Platform of Okomera.
21 people are employed at Okomera.
Okomera is based in Paris, Île-de-France.